Who We Are
Cytovation builds on over 15 years of cutting-edge research from two leading Norwegian institutions; University of Bergen and Haukeland University Hospital. Led by a highly experienced management team and world-renowned experts in tumour biology, an extensive research program has focused on engineering synthetic peptides with unique properties. CyPep-1, the company’s lead candidate, is being developed as a first-in-class lytic agent for the treatment of solid tumors.